- Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec
- The Radixact System is equipped with ClearRT™ and Synchrony®, advanced technologies designed to improve treatment outcomes for more patients each day
MADISON, Wis., Feb. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec's Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is the first in Canada to treat cancer patients using the company's Radixact® radiation therapy delivery system. According to the Quebec Cancer Foundation, "on average in Quebec, someone learns that they have cancer every 8 minutes1," reinforcing the need for innovative new care options like the Radixact System that effectively manage the disease while minimizing the radiation dose to healthy tissue and associated risk of side effects that can impact daily life. A second Radixact System is scheduled to be installed mid-2024.
The Radixact System at the Montérégie center has been augmented with the Accuray exclusive ClearRT™ helical fan-beam kVCT imaging solution and Synchrony® motion adaptation technology. ClearRT can produce exceptional, diagnostic-like quality CT images while Synchrony enables clinicians to track, detect and correct for tumor movement in real-time, providing medical care teams with the tools to help improve radiation therapy department workflows and patient outcomes, and rapidly deliver treatments.
"Our goal at Accuray is to design radiation therapy solutions that can take on the most complex challenges — while making commonly treatable cases even easier — so patients get back to living their lives, faster. We are honored to partner with the Montérégie Integrated Cancer Center team to bring a new approach for the treatment of cancer to the people in the province of Quebec. With the installation of the Radixact System, ClearRT and Synchrony, the Montérégie team is setting a new standard for precision and accuracy in radiation therapy and making this form of care an option for more cancer patients," said Suzanne Winter, president and CEO of Accuray.
The Radixact System provides a non-invasive option for the treatment of a wide range of cancerous and non-cancerous tumors throughout the body — from small to large tumors, multiple tumors, those located in hard-to-reach areas and recurrent tumors, to cancers of the skin and blood. The system can be used in combination with surgery, chemotherapy and other medications. It also can be used as part of the pre-conditioning regimen before a bone marrow transplant, either alone or with chemotherapy, to neutralize any cancer in the marrow.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations regarding the treatment of cancer in Quebec, Canada; expectations regarding installation of a second Radixact at the Monteregi Integrated Cancer Center; clinical applications; clinical results; patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 7, 2024, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
¹ https://cancerquebec.ca/en/information-about-cancer/the-cancer/statistics/#:~:text=In%202023%2C%2067%2C548%20Quebecers%20were,of%20aging%20and%20population%20growth.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quebec-cancer-center-is-first-in-canada-to-treat-cancer-patients-using-the-accuray-radixact-system-302060306.html
SOURCE Accuray Incorporated
